首页> 外文期刊>Drug development and industrial pharmacy >Strategies to improve dissolution and oral absorption of glimepiride tablets: solid dispersion versus micronization techniques.
【24h】

Strategies to improve dissolution and oral absorption of glimepiride tablets: solid dispersion versus micronization techniques.

机译:改善格列美脲片的溶解和口服吸收的策略:固体分散与微粉化技术。

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this study is to compare two different dissolution-enhancing strategies, solid dispersion (SD) and micronized techniques, for improving oral absorption of poorly soluble glimepiride, and to decide which strategy is suitable for its solubilization. The formulation of glimepiride SD was prepared by a solvent-evaporation process with povidone k-30 (PVPk30) at a weight ratio of 1:9 (drug:carrier). The other was prepared via a modified micronization technique, where glimepiride was premilled together with lactose and Lutrol F68 until the milled material passes through a 500 mesh ASTM sieve (30 mum). The dissolution results indicated that the two techniques were both capable of enhancing the dissolution rate and extent of glimepiride. The release profiles of the two prepared products were similar to the marketed product (Amaryl(R)) in various types of dissolution media. Furthermore, the oral bioavailability was evaluated for the three formulations in fasted beagle dogs. Statistical analysis indicated that there were no significant differences in pharmacokinetic parameters among the two prepared formulations and a marketed product, especially for AUC, C(max), and T(max). The dissolution parameters (D and AUC) in Tris buffer demonstrated the good in vitro/in vivo relationship with T(max) values for the three formulations. In conclusion, our studies confirmed that both SD and micronization techniques were capable of improving dissolution and oral absorption of glimepiride tablets to a similar extent as the marketed product, and the three glimepiride tablets were bioequivalent in the case of the rate and extent of absorption in dogs.
机译:这项研究的目的是比较两种不同的提高溶出度的策略,即固体分散(SD)和微粉化技术,以改善难溶性格列美脲的口服吸收,并确定哪种策略适合其增溶。格列美脲SD的制剂通过溶剂蒸发法以聚维酮k-30(PVPk30)以1:9的重量比(药物:载体)制备。另一种通过改进的微粉化技术制备,其中格列美脲与乳糖和Lutrol F68一起预研磨,直到研磨后的物料通过500目ASTM筛(30毫米)。溶出结果表明,两种技术均能够提高格列美脲的溶出速率和程度。两种制备的产物在各种类型的溶解介质中的释放曲线与市售产物(Amaryl)相似。此外,在禁食比格犬中评估了三种制剂的口服生物利用度。统计分析表明,两种制备的制剂和市售产品之间的药代动力学参数没有显着差异,特别是对于AUC,C(max)和T(max)。 Tris缓冲液中的溶出参数(D和AUC)表明三种配方的T / max值具有良好的体外/体内关系。总之,我们的研究证实,SD和微粉化技术均能够将格列美脲片的溶解度和口服吸收提高到与市售产品相似的程度,并且三种格列美脲片在吸收率和程度方面具有生物等效性。小狗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号